Search Results - "Stinchcombe, T"

Lorlatinib in the treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer by Stinchcombe, T.E.

Get full text

Biomarker-directed molecularly targeted therapy: the importance of prospective evaluation by Stinchcombe, T.E.

Get full text

Erlotinib in African Americans With Advanced Non-Small Cell Lung Cancer: A Prospective Randomized Study With Genetic and Pharmacokinetic Analyses by Phelps, M A, Stinchcombe, T E, Blachly, J S, Zhao, W, Schaaf, L J, Starrett, S L, Wei, L, Poi, M, Wang, D, Papp, A, Aimiuwu, J, Gao, Y, Li, J, Otterson, G A, Hicks, W J, Socinski, M A, Villalona-Calero, M A

“…Prospective studies on epidermal growth factor receptor (EGFR) inhibitors in African Americans with non–small cell lung cancer (NSCLC) have not previously been…”
Get full text

A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations by Villaruz, L.C., Wang, X., Bertino, E.M., Gu, L., Antonia, S.J., Burns, T.F., Clarke, J., Crawford, J., Evans, T.L., Friedland, D.M., Otterson, G.A., Ready, N.E., Wozniak, A.J., Stinchcombe, T.E.

“…For patients with stage IV non-small-cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions and exon 21 L858R mutations, osimertinib…”
Get full text

A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC) by Stinchcombe, T.E., Janne, P.A., Wang, X., Bertino, E.M., Weiss, J.M., Bazhenova, L., Gu, L., Lau, C.J., Paweletz, C.P., Jaslowski, A.J., Gerstner, G.J., Baggstrom, M.Q., Graziano, S.L., Bearden, J., Vokes, E.E.

Get full text

A pooled analysis of individual patient data (IPD) of concurrent chemoradiotherapy for limited-stage small cell lung cancer (LS-SCLC) in elderly compared to younger patients (pts) who participated in US National Cancer Institute cooperative group studies by Stinchcombe, T.E., Fan, W., Schild, S.E., Vokes, E.E., Bogart, J., Le, Q.-T.X., Thomas, C.R., Edelman, M., Horn, L., Komaki, R., Cohen, H.J., Ganti, A.K., Pang, H., Wang, X.

Get full text

Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance) by Urbanic, J.J, Wang, X, Bogart, J.A, Stinchcombe, T, Hodgson, L, Schild, S.E, Bazhenova, L, Salgia, R, Vokes, E.E

Get full text

Safety Data Analyses for First-Line Pemetrexed Plus Carboplatin (Pem+Cb) in Nonsquamous Non-Small Cell Lung Cancer (ns-NSCLC) by Okamoto, I, Schuette, W, Stinchcombe, T, Rodrigues Pereira, J, Liu, J, San Antonio, B, John, W, Chen, J, Zinner, R

Get full text

Switch Maintenance With Sunitinib (S) in Advanced Non-Small Cell Lung Cancer (NSCLC): An Alliance (CALGB 30607), Randomized, Placebo-Controlled Phase 3 Trial by Socinski, M.A, Wang, X, Baggstrom, M, Gu, L, Stinchcombe, T, Edelman, M, Baker, S, Mannuel, H, Crawford, J, Vokes, E

Get full text

3094 Nivolumab (NIVO) safety profile: Summary of findings from trials in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC) by Gettinger, S.N, Horn, L, Ramalingam, S.S, Spigel, D.R, Paz-Ares, L, Paik, P, Reck, M, Reckamp, K, Mazières, J, Stinchcombe, T, Lynch, M, Brahmer, J

Get full text

Bevacizumab in the treatment of non-small-cell lung cancer by Stinchcombe, T E, Socinski, M A

“…Lung cancer is the leading cause of cancer death in the United States. The majority of patients present with advanced disease, and treatment with standard…”
Get full text

The dysfibrinogenaemias by Roberts, Harold R., Stinchcombe, Thomas E., Gabriel, Don A.

Get full text

PCR234 Patient and Oncologist Preferences for Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer (ALK+ aNSCLC) Tyrosine Kinase Inhibitors (TKIs) Treatments in the First Line (1L) Setting by Le, H, Coulter, J, Cappelleri, J, Lu, H, Quaife, M, Meginnis, K, Fernandez, G, Culver, KW, Vaghela, S, Thomaidou, D, Stinchcombe, T

Get full text

1546P Impact of stratification factors on outcomes in limited-stage small cell lung cancer: Analysis of CALGB 30610 (Alliance)/RTOG 0538 by Bogart, J., Wang, X., Masters, G., Gao, J., Komaki, R., Gaspar, L.E., Heymach, J., Bonner, J.A., Kuzma, C., Waqar, S.N., Petty, W.J., Stinchcombe, T., Bradley, J.D., Vokes, E.E.

Get full text

557TiP SGNTUC-019: Phase II basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations by Reck, M., Okines, A., Pohlmann, P.R., Yu, E., Bekaii-Saab, T., Nakamura, Y., Monk, B.J., O'Malley, D., Kang, V., Walker, L.N., Stinchcombe, T.

Get full text

Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on the experimental thoracic radiotherapy (TRT) arms of CALGB 30610 (Alliance) / RTOG 0538 by Bogart, J., Wang, X., Masters, G., Zhu, H., Komaki, R., Gaspar, L., Dobelbower, M.C., Kuzma, C., Heymach, J., Vokes, E.E., Stinchcombe, T.

Get full text

1737OInterim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on the experimental thoracic radiotherapy (TRT) arms of CALGB 30610 (Alliance) / RTOG 0538 by Bogart, J, Wang, X, Masters, G, Zhu, H, Komaki, R, Gaspar, L, Dobelbower, M C, Kuzma, C, Heymach, J, Vokes, E E, Stinchcombe, T

“…Abstract Background The optimal TRT regimen for LSCLC remains to be defined. CALGB 30610/RTOG 0538 started as a 3 arm study designed to discontinue one of 2…”
Get full text

1737O - Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on the experimental thoracic radiotherapy (TRT) arms of CALGB 30610 (Alliance) / RTOG 0538 by Bogart, J., Wang, X., Masters, G., Zhu, H., Komaki, R., Gaspar, L., Dobelbower, M.C., Kuzma, C., Heymach, J., Vokes, E.E., Stinchcombe, T.

“…The optimal TRT regimen for LSCLC remains to be defined. CALGB 30610/RTOG 0538 started as a 3 arm study designed to discontinue one of 2 experimental TRT arms…”
Get full text

Comparison of chemoradiotherapy treatment strategies in stage III non-small cell lung cancer among elderly patients from multiple data sources by Pang, H., Stinchcombe, T., Cheng, P., Lee, A.W., Lee, V.H., Vokes, E.E., Wang, X.

Get full text

1268P JASPER: Efficacy and safety of first-line (1L) niraparib plus a programmed death receptor 1 inhibitor (PD-1i) in patients with advanced non-small cell lung cancer (NSCLC) by Ramalingam, S.S., Thara, E., Rao, S., Awad, M.M., Dowlati, A., Haque, B., Veatch, A.L., Stinchcombe, T., Dy, G.K., Spigel, D.R., Singh, N. Iyer, Evilevitch, L., Wang, Z., Tang, Y., Teslenko, I., Roychoudhury, M.

Get full text